Clinical Trial

A Clinical Study to Evaluate SM17 for Atopic Dermatitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial is a phase 2, randomized, double-Blind, placebo-Controlled, dose-finding clinical study conducted in participants with moderate-to-severe atopic dermatitis. The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics , and pharmacodynamics of SM17 (subcutaneous injection) in participants with moderate to severe atopic dermatitis.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-07
Trial Details
NCT Number NCT07445919
Lead Sponsor SinoMab BioScience Ltd
Conditions Atopic Dermatitis
Enrollment 200 participants
Start Date 2026-03-31
Primary Completion 2027-04-25 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-06